Skip to content

Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome

Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome and Epiretinal Membrane or Macular Hole: a Pilot Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07506551
Enrollment
24
Registered
2026-04-01
Start date
2023-07-06
Completion date
2026-12-01
Last updated
2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudoexfoliation Syndrome

Keywords

pseudoexfoliation syndrome, vitreous, proteomics

Brief summary

Determination of proteins and their levels in the vitreous of eyes with or without pseudoexfoliation syndrome (PEX)

Detailed description

Pseudoexfoliation syndrome (PEX) is a systemic disorder that leads to the deposition of extracellular material in various tissues, particularly in the anterior segment of the eye. This material consists mainly of elastic microfibrils. PEX is believed to be an age-related condition whose incidence and prevalence vary by region but increase in patients over 50 years of age. Due to demographic changes, the number of PEX patients is expected to rise, making it important to understand this condition, its pathogenesis, and its complications. The pathogenesis of PEX syndrome has not yet been fully elucidated. The interplay of growth factors, oxidative stress, inflammation, and cellular damage is described as a key factor in the development of the disease. Detailed immunohistochemical and biochemical studies have shown that several proteins are heavily involved in the pathogenesis of PEX. The anterior segment of the eye is frequently affected by PEX, where the PEX material is present in the aqueous humor, and its accumulation leads to visible deposits on the anterior lens capsule, the edge of the pupil, or the anterior chamber angle. Several proteomics studies of the aqueous humor have been conducted, demonstrating that oxidative stress and inflammation contribute to the development of PEX. However, there is a lack of studies on PEX and its effects on the posterior segment. Some studies suggest that the posterior segment is primarily affected. Interestingly, PEX has recently been linked to diseases/pathologies of the vitreoretinal interface (VRI). It has been shown that the rates of posterior vitreous detachment (PVD) and epiretinal membranes (ERM) are higher in eyes with PEX. The pathogenesis of ERM is not fully understood, but similar to PEX, inflammation, inflammatory proteins, and cytokines appear to play an important role in the development of ERM. To further investigate the differences in proteins and their levels in the vitreous humor of PEX and non-PEX eyes, the aim of the study is to perform a non-targeted proteomic analysis using liquid chromatography coupled with mass spectrometry (LC-MS) of the vitreous humor from PEX eyes with ERM, compared to vitreous humor without PEX but with ERM.

Interventions

OTHERLiquid chromatography mass spectrometry

Proteomic analysis of vitreous samples of patients with epiretinal membranes or macular holes with or without pseudoexfoliation syndrome using Liquid chromatography mass spectrometry

Sponsors

Prim. Prof. Dr. Oliver Findl, MBA
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 105 Years
Healthy volunteers
No

Inclusion criteria

* PEX syndrome * Macular pucker or macular hole and scheduled for vitrectomy * Age 21 or older * Written informed consent prior to surgery

Exclusion criteria

* Previous vitrectomy or intravitreal application of drugs * Systemic anti-inflammatory drugs * Pre- surgical topical anti-inflammatory drugs (NSAR, Steroids) * Pre- surgical topical prostaglandins * Diabetic retinopathy * AMD * PEX Syndrome only in the contralateral eye (the eye not scheduled for surgery)

Design outcomes

Primary

MeasureTime frameDescription
Protein levels24 monthsProtein levels in vitreous samples of patients with and without pseudoexfoliation syndrome will be measured using Liquid chromatography mass spectrometry

Countries

Austria

Contacts

PRINCIPAL_INVESTIGATOROliver Findl, Prim. Univ. Prof. Dr.

Vienna Institute for Research in Ocular Surgery (VIROS)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026